Tuesday, January 20, 2026

GOLD - New High $4,800

Gold hit another new all-time high in price, now over $4,800 per ounce. What's driving the price higher? A reshaping of our geo-political world, in addition to the US debt which continues to climb, now at 38 trillion. The cost of servicing debt (which consists of making regular interest and principle payments on borrowed funds), is 1.2 trillion annually. Chart of federal government interest payments below, followed by a weekly chart of $GOLD.


Monday, January 12, 2026

NUVB: Nuvation Bio - Update #8

Nuvation Bio has updated investors with the good news of a European partnership, to sell newly FDA approved and commercialized drug Ibtrozi in Europe and other countries outside of the US, for patients with Ros1 NSCLC. Like many other US based companies, they utilize partnerships outside the US who already have a footprint of sales professionals actively selling similar products in the field. Under this agreement completed today with Eisai, there is upfront, milestones and a royalty kick back to the owner of the product, in this case Nuvation Bio. The selling partner reaps the revenue abroad. A win / win cost effective scenario. Below are the Royalty agreements that are now in place outside of the US for Nuvation Bio (NUVB). 

China: Innovent Biologics 
(Dovbleron) First and second-line approval.
-Milestone payments up to $189 million
-Tiered royalty payments based on annual net sales of Taletrectinib

Europe: Eisai
-60 million upfront 
-170 million milestone payments
-10% to 19% tiered royalty payments from net sales of Taletrectinib

Japan: Nippon Kayaku
-Milestone payments based on domestic sales exceeding certain amounts
-Royalty based on domestic net sales

Monday, January 5, 2026

HELUS Pharma: Formerly Cybin - Update #4

Cybin whom we wrote about here Cybin history, has changed their name and ticker symbol as they have moved from the NYSE exchange to the Nasdaq exchange starting on January 5th. The companies name is now Helus Pharma with ticker symbol HELP. The move suits the companies prospects better trading on the Nasdaq, because of their focus on growth-oriented development. Chart of HELP below.